1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

07 Jul 2023
Admin
News Article

Tiumbio And Hansoh Pharma Announce Clinical Trial Approval Of Hs-10518/Tu2670

Tiumbio And Hansoh Pharmaceutical Group Announced That The China National Medical Products Administration (Nmpa) Has Granted Approval For Hansoh'S Investigational New Drug (Ind) Application For The Clinical Study Of Hs-10518, Also Known As Tu2670. The Focus Of The Study Is To Evaluate The Potential Of Hs-10518 In Managing Moderate To Severe Pain Associated With Endometriosis.Tu2670, Also Referred To As Hs-10518, Is A Promising Investigational Non-Peptide Gonadotropin-Releasing Hormone (Gnrh) Antagonist That Can Be Taken Orally. It Is Being Developed As A Potential Treatment For Endometriosis And Uterine Fibroids. This Drug Aims To Provide Enhanced Convenience In Terms Of Dosing And Exhibits A Superior Safety Profile When Compared To Current Treatment Options.Endometriosis Is A Condition Where The Endometrial Tissue, Which Normally Lines The Inside Of The Uterus, Grows Outside The Uterus. It Can Cause Various Symptoms Such As Severe Pelvic Pain, Menstrual Pain, Lower Abdominal Pain, And Infertility. It Affects Approximately 11 Percent Of Women Of Childbearing Age, And It Is Estimated That There Are About 18 Million Patients With Endometriosis In Europe.The Ind Approval From The Nmpa Paves The Way For Further Clinical Studies Of Tu2670 In China. This Approval Represents A Significant Step Forward In The Field Of Endometriosis Treatment, Offering Hope For Improved Options And Better Outcomes For Patients In China.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!